MIA
MIA SH3 domain containing
Gene Context Sentence
Table 2. Analysis of context sentence of MIA gene in 5 abstracts.
| PMID | Gene Context Sentence |
|---|---|
| 32380209 | Isolate I0305/19 and other GI-19 viruses isolated in China have the amino acid sequence MIA at positions 110-112 in the S protein. |
| 32420954 | Anosmia and dysgeusia have been reported as particular symptoms.4,5 Notably, these sensory symptoms seem to have a peculiar trend, such as usually precede the onset of respiratory symp- toms. […] Anos- mia and dysgeusia frequently preceded respiratory complaints. […] Anosmia and dysgeusia seem to be short-lived and self-resolving in COVID-19, thus a neurotoxic effect swiftly disappearing and/or cytopathic damage could be hypothesized similarly to other viral infections. |
| 32443177 | In order to follow biosafety recommendations, we used Ultrasound-Guided Minimally Invasive Autopsy (MIA-US) to assess the systemic involvement of COVID-19 and present the results of ten initial autopsies. […] We used MIA-US for tissue sampling of lungs, liver, heart, kidneys, spleen, brain, skin, skeletal muscle and testis for histology and RT-PCR to detect SARS-COV-2-RNA. […] MIA-US is safe and effective for the study of severe COVID-19. |
| 32505774 | IgM/IgG and total antibodies against SARS-CoV-2 were measured by a cyclic enhanced fluorescence assay (CEFA) and a microsphere immunoassay (MIA), respectively. […] Independent performance evaluation included imprecision, reproducibility, specificity and cross-reactivity (CEFA n = 320, MIA n = 364). […] Agreement of CEFA and MIA was 90.4%-94.5% (Kappa: 0.81-0.89) in 302 samples. […] CEFA and MIA detected SARS-CoV-2 antibodies in 26.2% and 26.3%, respectively, of ED patients. […] Longitudinal antibody kinetic changes by CEFA and MIA measurements correlated well and exhibited three types of seroconversion. […] Rigorously validated CEFA and MIA assays are reliable for detecting antibodies to SARS-CoV-2 and show promising clinical utility when evaluating immune response in hospitalized and convalescent patients, but are not useful for early screening at patient’s initial ED visit. |
| 33175911 | Minimally invasive autopsy (MIA) is a validated and safe method to establish the cause of death (COD), mainly in low-resource settings. […] However, the additional clinical value of MIA in Coronavirus disease (COVID-19) patients in a high-resource setting is unknown. […] The objective was to assess if and how MIA changed clinical COD and contributing diagnoses in deceased COVID-19 patients. […] MIA consisted of whole-body CT and CT-guided Tru-Cut® biopsies. […] MIA COD and contributing diagnoses were established during a multi-disciplinary meeting. […] The main outcomes were alterations in CCOD and contributing diagnoses after MIA, and the contribution of each diagnostic modality. […] MIA led to an alteration in 15/18 (83%) patients. […] MIA found a new COD (1/5), a more specific COD (1/5), a less certain COD (1/5), or a contributing diagnosis to be the COD (2/5). […] MIA, especially histological examination, can add valuable new clinical information regarding the cause of death in COVID-19 patients, even in a high-resource setting with wide access to premortem diagnostic modalities. […] MIA may provide important clinical insights and should be applied in the current ongoing pandemic. |